Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA7 | P43166 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15709749 | 0.85 | CA5A (0.52) | CA5AMEN1HPGDKMT2ALMNA | |
| SCHEMBL343284 | 0.85 | CA5A (0.52) | CA5AMEN1HPGDKMT2ALMNA | |
| SCHEMBL96189 | 0.83 | CA5A (1.00) | CA5AMEN1CYP3A4HPGDKMT2A | |
| SCHEMBL7307023 | 0.83 | CA5A (0.89) | CA5AMEN1CYP3A4HPGDKMT2A | |
| SCHEMBL10546235 | 0.81 | CES2 (0.44) | CA5ACYP3A4MTORCA12CA1 | |
| Water SCHEMBL3182721 | 0.80 | CA5A (0.94) | CA5AMEN1CYP3A4HPGDKMT2A | |
| SCHEMBL29422455 | 0.79 | CA12 (0.68) | CA5AMEN1CYP3A4HPGDKMT2A | |
| SCHEMBL29547990 | 0.79 | TPMT (0.46) | CA5AMEN1HPGDKMT2ALMNA | |
| SCHEMBL200289 | 0.79 | CA12 (0.68) | CA5AMEN1CYP3A4HPGDKMT2A | |
| SCHEMBL7786069 | 0.79 | TPMT (0.46) | CA5AMEN1HPGDKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| US-9938204-B2 | Intermolecular C-H silylation of unactivated arenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938204-B2 | Intermolecular C-H silylation of unactivated arenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160200639-A1 | INTERMOLECULAR C-H SILYLATION OF UNACTIVATED ARENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-14 | — | — | US | disclosed |
| US-20160200639-A1 | INTERMOLECULAR C-H SILYLATION OF UNACTIVATED ARENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-14 | — | — | US | disclosed |
| EP-2411358-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200639-A1 | INTERMOLECULAR C-H SILYLATION OF UNACTIVATED ARENES | CCNH, CTTN, CCRL2 | CA5A 3854/4885MEN1 3031/4885CYP3A4 101/4885 |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | CA5A 2226/4885MEN1 4324/4885CYP3A4 402/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | CA5A 41/4885MEN1 1354/4885CYP3A4 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.